Literature DB >> 34808012

Oral squamous cell carcinoma outcome in adolescent/young adult: Systematic review and meta-analysis.

Estela Kaminagakura1,2, Rubens Nisie Tango3, Danyel Cruz-Perez4, Roberta Bonan4, Luciana Yamamoto de Almeida5, Maria Letícia de Almeida Lança1, Paulo Bonan6, Hélder Martins7, Ademar Takahama8, Fábio Augusto Ito8, Cláudia Malheiros Coutinho-Camillo9, Silvia Vanessa Lourenço10, Taciana Caneppele11, Andrew G Sikora12, Luiz Paulo Kowalski13,14, Simon Young2.   

Abstract

To perform a systematic review focusing on the prognosis of oral cavity squamous cell carcinoma (OSCC) in young patients (≤40 years old) compared to older (>40 years old). Four databases were used in our search strategy. First, all titles were systematically organized using the Covidence platform online. In the second phase, 118 full texts of potentially eligible studies were analyzed by reviewers independently and in pairs. Twelve studies were considered eligible for data extraction. The relapse was higher in the young than in controls (pooled relative risk (RR) = 1.31; 95% CI [1.10-1.56]). The 5-year disease-free survival (DFS) was worse in young group (pooled hazard ratio (HR) = 0.73; 95% CI [0.63-0.85]) but the 5-year overall survival (OS) estimate was similar between the groups (pooled HR = 0.84; 95% CI [0.70-1.00]). While the 5-year OS was similar between groups, the number of relapses and 5-year DFS were worse in patients with OSCC ≤40 years old.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  disease-free survival; overall survival; prognosis; relapse; young

Mesh:

Year:  2021        PMID: 34808012     DOI: 10.1002/hed.26940

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Inflammation and Invasion in Oral Squamous Cell Carcinoma Cells Exposed to Electronic Cigarette Vapor Extract.

Authors:  Hannah P Robin; Courtney N Trudeau; Adam J Robbins; Emily J Chung; Erum Rahman; Olivia L Gangmark Strickland; Scott Jordan; Frank W Licari; Duane R Winden; Paul R Reynolds; Juan A Arroyo
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.